Why Mesoblast Limited’s (MESO) Stock Is Up 16.88%
As of Thursday, October 29, Mesoblast Limited’s MESO share price has surged by 16.88%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Cynthia McLaughlin
Tudor Pop
Rosalio Madrigal
| Share Statistics | MESO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,702.7 | $211.8 | 53% |
|
| Shares Out (Mil) | 1,297.7 | 55.4 | 95% |
|
| Institutional Ownership | 43.4% | 93.0% | 18% |
|
| Float (Mil) | 830.6 | 41.5 | 89% |
|
| Beta | 0.81 | 0.99 | 47% |
|
| Avg Daily Volume (000s) | 228 | 553 | 46% |
|
| Price Change (52-week) |
(15.5%) | 42.8% | 38% |
|
| Growth | MESO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 74.7% | 13.2% | 98% |
|
| Net Income (5yr) | 10.3% | (10.3%) | 56% |
|
| EPS (5yr) | 23.0% | 15.8% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.6%) | (15.7%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MESO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $120 | $41 | 28% |
|
| Net Income (TTM) (Mil) | ($58) | ($44) | 15% |
|
| EPS (TTM) | ($0.044) | ($1.500) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($44) | ($35) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($59) | $-0 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $114 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $2,201 | $147 | 51% |
|
| Valuation | MESO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 30.14 | 2.01 | 97% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MESO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.0% | 67.9% | 89% |
|
| Net Margin | (47.8%) | (50.6%) | 11% |
|
| ROA | (7.4%) | (47.4%) | 26% |
|
| ROE | (9.9%) | (53.1%) | 27% |
|
| Liabilities to Assets | 26.5% | 29.7% | 18% |
|
| F-Score | 5 | 3 | 50% |
|
Mesoblast Limited did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors